Recently, a number of therapies have been approved that provide more treatment options and improve outcomes for men with advanced prostate cancer. This debate meeting will provide an opportunity to review the latest data on treatment in both the pre- and post-chemotherapy settings. We will also address key topics on the management of patients with metastatic castration-resistant prostate cancer (CRPC) in daily clinical practice.

In the first session, we will discuss the mechanisms of action and the possible mechanisms of resistance of the newer agents being approved for metastatic CRPC treatment. We will move through the metastatic CRPC treatment continuum, debating options for patients who have never received chemotherapy, indicators for starting chemotherapy, and treatment options after chemotherapy. We will also evaluate quality of life as an endpoint in both clinical trials and clinical practice, and discuss the practical considerations in different clinical settings, including the management of elderly and comorbid patients with metastatic CRPC.

Panel discussion sessions are included throughout the program to exchange and share experiences relevant to everyday clinical practice. In addition, towards the end of the day, an interactive workshop will provide the opportunity to discuss some topics in greater detail in smaller groups with experts.

We look forward to this Prostate Cancer Debate and hope you will make time to join us for what promises to be a stimulating, educational, and interactive program.